PSA-specific and non-PSA-specific conversion of a PSA-targeted peptide conjugate of doxorubicin to its active metabolites

Drug Metabolism and Disposition

Volumn 29, Issue 3, 2001, Pages 313-318

  Wong, B K ^a   Defeo Jones, D ^a   Jones, R E ^a   Garsky, V M ^a   Feng, D M ^a   Oliff, A ^a   Chiba, M ^a   Ellis, J D ^a   Lin, J H ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; PEPTIDE; PRODRUG; PROSTATE SPECIFIC ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CARDIOTOXICITY; DOG; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG METABOLISM; DRUG STRUCTURE; DRUG TARGETING; HUMAN; HUMAN CELL; MALE; MONKEY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOTRANSFORMATION; DOXORUBICIN; DRUG DELIVERY SYSTEMS; HUMANS; LIVER; MALE; MICE; MICE, NUDE; MOLECULAR STRUCTURE; NEOPLASM TRANSPLANTATION; OLIGOPEPTIDES; PRODRUGS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TUMOR CELLS, CULTURED; VERAPAMIL;

ANIMALIA; CANIS FAMILIARIS; MUS MUSCULUS;

EID: 0035111756     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Chemotherapy in advanced prostate cancer
2. Anthracycline antibiotics in cancer therapy in antineoplastic therapy
3. Human pharmacokinetics of N-L-leucyl-doxorubicin, a new anthracycline derivative, and its correlation with clinical toxicities
4. A peptide-doxorubicin prodrug activated by prostate-specific antigen selectively kills prostate tumor cell positive for prostate-specific antigen in vivo
5. Specific and efficient peptide substrates for assaying the proteolytic activity of prostate-specific antigen
6. Phase 1 and pharmacokinetic study of L-377202, a novel peptide doxorubicin conjugate in patients with advanced prostate cancer
7. LNCaP model of human prostate carcinoma
8. Tumor selective delivery of 5-fluorouracil by capecitubine, in human tumor xenografts
9. Seminogelin, the predominant protein in human semen
10. Prostate-specific antigen in serum occurs predominantly in complex with alphal-antichymotrypsin
11. Mapping of the unique enzyme characteristics of PSA
12. Prostate-specific antigen forms complexes with human alpha2-macroglobulin and binds to the alpha2-macroglobulin receptor/LDL receptor related protein
13. Liver perfusion studies in drug metabolism and drug toxicity
14. A commentary: Methods and assumptions in the kinetic estimation of metabolite formation
15. Evolving strategies of cytotoxic chemotherapy for advance prostate cancer
16. Pharmacokinetics considerations of regional administration and drug targeting: Influence of site of input in target tissue and flux of binding protein
17. Doxorubicin-induced cardiomyopathy
18. Clinical pharmacokinetics of doxorubicin
19. Role of the MDR-1-encoded multiple drug resistance phenotype in prostate cancer cell lines
20. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: A review